Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - ACOG says it will no longer accept federal funding
- Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
